Results 221 to 230 of about 34,901 (267)

Evaluation of Various Antimicrobial Susceptibility Tests for Novel β-Lactam/β-Lactamase Inhibitors against Carbapenem-Resistant Pathogens

Young Ah Kim, Cheonggyu Lee, Kyoung Ja Jang, Heejung Kim   +3 more
openalex   +2 more sources

Activity of cefiderocol against <i>Pseudomonas aeruginosa</i> from the USA and Europe (2020-2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program. [PDF]

Microbiol Spectr
Kimbrough JH, Karr MH, Nguyen ST, DeJonge BLM, Longshaw C, Takemura M, Yamano Y, Castanheira M, Mendes RE.   +8 more
europepmc   +1 more source

Aza-boronic acids as non-β-lactam inhibitors of AmpC-β-lactamase

, 2004
Valentina Buzzoni, Jesús Blázquez, Stefania Ferrari, Samuele Calò, Alberto Venturelli, Maria Paola Costi   +5 more
openalex   +2 more sources

Therapeutic drug monitoring (TDM) of β-lactam/β-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study. [PDF]

J Antimicrob Chemother
O'Jeanson A, Nielsen EI, Friberg LE.
europepmc   +1 more source

Synthesis and Preclinical Evaluation of TPA-Based Zinc Chelators as Metallo-β-lactamase Inhibitors

, 2018
Christian Schnaars, Geir Kildahl‐Andersen, Anthony Prandina, Roya Popal, Sylvie Radix, Marc Le Borgne, Tor Gjøen, Adriana Magalhães Santos Andresen, Adam Heikal, Ole Andreas Økstad, Christopher Fröhlich, Ørjan Samuelsen, Silje Lauksund, Lars Petter Jordheim, Pål Rongved, Ove Alexander Høgmoen Åstrand   +15 more
openalex   +2 more sources

ARGONAUT-IV: susceptibility of carbapenemase-producing <i>Klebsiella pneumoniae</i> to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten. [PDF]

Antimicrob Agents Chemother
Jacobs MR, Good CE, Abdelhamed AM, Mack AR, Bethel CR, Marshall SH, Hujer AM, Hujer KM, Patel R, van Duin D, Fowler VG, Rhoads DD, Six DA, Moeck G, Uehara T, Papp-Wallace KM, Bonomo RA.   +16 more
europepmc   +1 more source

Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii. [PDF]

Future Microbiol
McLeod SM, O'Donnell JP, Narayanan N, Mills JP, Kaye KS.   +4 more
europepmc   +1 more source

Detection and inhibition of β-lactamase activity in clinical isolates of Escherichia coli combining β-lactamase and efflux inhibitors using an MTT-based method: phenotypic and genotypic validation

, 2020
Débora Carvalho Serra
openalex   +1 more source

Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020-2022). [PDF]

BMC Pulm Med
Sader HS, Mendes RE, Ryan Arends SJ, Doyle TB, Castanheira M.   +4 more
europepmc   +1 more source